Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ: OBIO )

5.100 -0.450 (-8.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,178
Open 5.000
Bid (Size) 2.050 (2)
Ask (Size) 5.400 (1)
Prev. Close 5.550
Today's Range 4.950 - 5.415
52wk Range 4.220 - 20.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-41.91%
-41.91%
1 Month
+4.08%
+4.08%
3 Month
-28.27%
-28.27%
6 Month
-2.49%
-2.49%
1 Year
-65.02%
-65.02%

More News

Read More
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Top 4 Health Care Stocks That Should Keep You Up At Night
Via Benzinga
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Shares of Orchestra BioMed Jumped Tuesday
Via The Motley Fool
Exposures Product Safety
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.